HK1102500A1 - Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase - Google Patents
Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinaseInfo
- Publication number
- HK1102500A1 HK1102500A1 HK07110701A HK07110701A HK1102500A1 HK 1102500 A1 HK1102500 A1 HK 1102500A1 HK 07110701 A HK07110701 A HK 07110701A HK 07110701 A HK07110701 A HK 07110701A HK 1102500 A1 HK1102500 A1 HK 1102500A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibition
- compounds
- methods
- aurora kinase
- mitotic progression
- Prior art date
Links
- 102000003989 Aurora kinases Human genes 0.000 title 1
- 108090000433 Aurora kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000008600 mitotic progression Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Small-Scale Networks (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57165304P | 2004-05-14 | 2004-05-14 | |
US61722104P | 2004-10-08 | 2004-10-08 | |
PCT/US2005/016445 WO2005111039A2 (en) | 2004-05-14 | 2005-05-12 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1102500A1 true HK1102500A1 (en) | 2007-11-23 |
Family
ID=35262144
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07110701A HK1102500A1 (en) | 2004-05-14 | 2007-10-03 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
HK08110327.5A HK1114853A1 (en) | 2004-05-14 | 2008-09-18 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
HK14112844.7A HK1199254A1 (en) | 2004-05-14 | 2014-12-23 | Process for the preparation of aurora kinase inhibitors |
HK15105404.2A HK1205102A1 (en) | 2004-05-14 | 2015-06-08 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08110327.5A HK1114853A1 (en) | 2004-05-14 | 2008-09-18 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
HK14112844.7A HK1199254A1 (en) | 2004-05-14 | 2014-12-23 | Process for the preparation of aurora kinase inhibitors |
HK15105404.2A HK1205102A1 (en) | 2004-05-14 | 2015-06-08 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
Country Status (26)
Country | Link |
---|---|
US (9) | US7572784B2 (xx) |
EP (4) | EP2746285B1 (xx) |
JP (4) | JP4467616B2 (xx) |
KR (3) | KR20120091275A (xx) |
CN (1) | CN104193750B (xx) |
AR (1) | AR049277A1 (xx) |
AT (1) | ATE381566T1 (xx) |
AU (1) | AU2005243175B2 (xx) |
BR (1) | BRPI0511139B8 (xx) |
CA (1) | CA2565411C (xx) |
CY (2) | CY1108092T1 (xx) |
DE (1) | DE602005003951T4 (xx) |
DK (1) | DK1771450T5 (xx) |
EA (1) | EA012112B1 (xx) |
ES (3) | ES2299080T3 (xx) |
HK (4) | HK1102500A1 (xx) |
HR (2) | HRP20080120T5 (xx) |
IL (1) | IL179063A (xx) |
MX (1) | MXPA06013042A (xx) |
MY (1) | MY139355A (xx) |
NZ (1) | NZ551370A (xx) |
PL (1) | PL1771450T3 (xx) |
PT (2) | PT1771450E (xx) |
RS (2) | RS52436B (xx) |
TW (1) | TWI338688B (xx) |
WO (1) | WO2005111039A2 (xx) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005111039A2 (en) * | 2004-05-14 | 2005-11-24 | Millennium Pharmaceuticals, Inc. | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
US7459448B2 (en) * | 2004-10-04 | 2008-12-02 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
EP1828165B1 (en) * | 2004-10-29 | 2013-03-20 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
AU2006241825A1 (en) | 2005-04-28 | 2006-11-09 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
AU2006243000B2 (en) * | 2005-05-05 | 2011-05-26 | Macrophage Pharma Limited | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US20090062302A1 (en) * | 2006-01-24 | 2009-03-05 | Buser-Doepner Carolyn A | Jak2 Tyrosine Kinase Inhibition |
JP2009530274A (ja) * | 2006-03-15 | 2009-08-27 | ワイス | ヒスタミン−3アンタゴニストとしてのn−置換−アザシクリルアミン化合物 |
CA2645583A1 (en) * | 2006-03-20 | 2007-09-27 | F. Hoffman-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
MX2008014743A (es) * | 2006-05-19 | 2008-12-01 | Wyeth Corp | N-benzoil- y n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3. |
US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
AU2012203952B2 (en) * | 2006-11-16 | 2014-12-11 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
AU2014280932B2 (en) * | 2006-11-16 | 2016-10-06 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
EP2155719A1 (en) * | 2007-05-24 | 2010-02-24 | Wyeth LLC | Azacyclylbenzamide derivatives as histamine-3 antagonists |
TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
WO2009012252A1 (en) * | 2007-07-16 | 2009-01-22 | Wyeth | Aminoalkylazole derivatives as histamine-3 antagonists |
EP2185504A2 (en) * | 2007-09-04 | 2010-05-19 | Biolipox AB | Bis-aromatic compounds useful in the treatment of inflammation |
TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
BRPI0817061A2 (pt) * | 2007-09-12 | 2015-03-24 | Wyeth Llc | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 |
JP2009108036A (ja) * | 2007-09-28 | 2009-05-21 | Fujifilm Corp | 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び/又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物 |
GB0803747D0 (en) * | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
WO2009106844A1 (en) * | 2008-02-29 | 2009-09-03 | Chroma Therapeutics Ltd. | Inhibitors of p38 map kinase |
US8138194B2 (en) | 2008-04-30 | 2012-03-20 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
US20110112193A1 (en) * | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
US7998952B2 (en) | 2008-12-05 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | Thiolactams and uses thereof |
ES2468391T3 (es) | 2008-12-22 | 2014-06-16 | Millennium Pharmaceuticals, Inc. | Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 |
WO2010103279A1 (en) | 2009-03-12 | 2010-09-16 | Biolipox Ab | Bis aromatic compounds for use as lct4 synthase inhibitors |
WO2010103278A1 (en) | 2009-03-12 | 2010-09-16 | Biolipox Ab | Bis aromatic compounds for use as ltc4 synthase inhibitors |
EP2429994A1 (en) | 2009-03-12 | 2012-03-21 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
EP2406223A2 (en) | 2009-03-12 | 2012-01-18 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
US8546377B2 (en) * | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
US8518933B2 (en) | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
CN104031049A (zh) * | 2010-02-19 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂的结晶形式 |
EP2545036A1 (en) | 2010-03-12 | 2013-01-16 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
CN103804391A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
JP6360881B2 (ja) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ |
CN103408552B (zh) * | 2013-07-25 | 2015-07-01 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
JP2018524292A (ja) * | 2015-07-21 | 2018-08-30 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラキナーゼインヒビターと化学療法剤の投与 |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
CN112062768B (zh) * | 2020-07-20 | 2021-08-31 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 具有Aurora激酶降解活性的小分子及其制备方法和应用 |
WO2023113457A1 (ko) * | 2021-12-14 | 2023-06-22 | (주)프레이저테라퓨틱스 | 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947585A (en) * | 1974-06-03 | 1976-03-30 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
US4022801A (en) | 1974-06-03 | 1977-05-10 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
US4028381A (en) | 1975-05-05 | 1977-06-07 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
US4099012A (en) * | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
US4318854A (en) * | 1979-02-07 | 1982-03-09 | Hoffmann-La Roche Inc. | Intermediates in the production of 2-benzazepines |
ZA80492B (en) * | 1979-02-07 | 1981-01-28 | Hoffmann La Roche | Benzazepine derivatives |
KR840000062B1 (ko) | 1979-02-07 | 1984-01-31 | 에프. 호프만-라롯슈 앤드 캄파니 아크티엔게젤샤프트 | 벤즈아제핀 유도체의 제조방법 |
SU1181547A3 (ru) | 1979-02-07 | 1985-09-23 | Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) | Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант) |
US4481142A (en) * | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
US4547581A (en) | 1979-02-07 | 1985-10-15 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines and intermediates in their preparation |
US4469633A (en) * | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
NL8102182A (nl) | 1981-05-04 | 1982-12-01 | Philips Nv | Kleurenbeeldbuis. |
EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
US5210082A (en) * | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
TW486480B (en) | 1996-03-08 | 2002-05-11 | Zeneca Ltd | Azolobenzazepine derivatives and compositions and method of use thereof |
US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
ATE233764T1 (de) | 1997-09-29 | 2003-03-15 | Meiji Seika Kaisha | Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel |
US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
PE20020451A1 (es) * | 2000-09-15 | 2002-06-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de cinasa proteina |
US20030105090A1 (en) * | 2000-12-21 | 2003-06-05 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
MXPA04001252A (es) | 2001-08-09 | 2004-05-27 | Actelion Pharmaceuticals Ltd | Nuevos heterociclos benzo-fusionados como antagonistas de endotelina. |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
WO2005111039A2 (en) * | 2004-05-14 | 2005-11-24 | Millennium Pharmaceuticals, Inc. | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
BRPI0517737A (pt) | 2004-11-17 | 2008-10-21 | Miikana Therapeutics Inc | inibidores de quinase |
WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
-
2005
- 2005-05-12 WO PCT/US2005/016445 patent/WO2005111039A2/en active Application Filing
- 2005-05-12 RS RS20120416A patent/RS52436B/en unknown
- 2005-05-12 KR KR1020127014200A patent/KR20120091275A/ko active Search and Examination
- 2005-05-12 BR BRPI0511139A patent/BRPI0511139B8/pt active IP Right Grant
- 2005-05-12 US US11/127,855 patent/US7572784B2/en active Active
- 2005-05-12 CA CA2565411A patent/CA2565411C/en active Active
- 2005-05-12 PT PT05779921T patent/PT1771450E/pt unknown
- 2005-05-12 PT PT07024446T patent/PT1905773E/pt unknown
- 2005-05-12 RS RS20080109A patent/RS50568B8/sr unknown
- 2005-05-12 EA EA200602100A patent/EA012112B1/ru not_active IP Right Cessation
- 2005-05-12 DK DK05779921.5T patent/DK1771450T5/da active
- 2005-05-12 CN CN201410345955.0A patent/CN104193750B/zh active Active
- 2005-05-12 EP EP13189940.3A patent/EP2746285B1/en active Active
- 2005-05-12 ES ES05779921T patent/ES2299080T3/es active Active
- 2005-05-12 MX MXPA06013042A patent/MXPA06013042A/es active IP Right Grant
- 2005-05-12 KR KR1020067026332A patent/KR101792651B1/ko active IP Right Grant
- 2005-05-12 ES ES10178391.8T patent/ES2540987T3/es active Active
- 2005-05-12 ES ES07024446T patent/ES2391577T3/es active Active
- 2005-05-12 JP JP2007513304A patent/JP4467616B2/ja active Active
- 2005-05-12 KR KR1020137013571A patent/KR101748290B1/ko active IP Right Grant
- 2005-05-12 EP EP13189935.3A patent/EP2719698B1/en active Active
- 2005-05-12 NZ NZ551370A patent/NZ551370A/en unknown
- 2005-05-12 EP EP05779921A patent/EP1771450B9/en active Active
- 2005-05-12 AU AU2005243175A patent/AU2005243175B2/en active Active
- 2005-05-12 MY MYPI20052151A patent/MY139355A/en unknown
- 2005-05-12 DE DE602005003951T patent/DE602005003951T4/de active Active
- 2005-05-12 EP EP10178391.8A patent/EP2261226B1/en active Active
- 2005-05-12 PL PL05779921T patent/PL1771450T3/pl unknown
- 2005-05-12 AT AT05779921T patent/ATE381566T1/de active
- 2005-05-13 TW TW094115612A patent/TWI338688B/zh active
- 2005-05-16 AR ARP050102001A patent/AR049277A1/es unknown
-
2006
- 2006-11-06 IL IL179063A patent/IL179063A/en active IP Right Grant
- 2006-12-21 US US11/643,600 patent/US20070185087A1/en not_active Abandoned
-
2007
- 2007-10-03 HK HK07110701A patent/HK1102500A1/xx unknown
-
2008
- 2008-03-17 CY CY20081100297T patent/CY1108092T1/el unknown
- 2008-03-19 HR HRP20080120TT patent/HRP20080120T5/hr unknown
- 2008-05-08 JP JP2008122788A patent/JP5148358B2/ja active Active
- 2008-09-18 HK HK08110327.5A patent/HK1114853A1/xx unknown
-
2009
- 2009-05-27 US US12/472,583 patent/US8399659B2/en active Active
-
2011
- 2011-09-16 JP JP2011203714A patent/JP2012006972A/ja not_active Withdrawn
-
2012
- 2012-10-02 HR HRP20120785TT patent/HRP20120785T1/hr unknown
- 2012-10-03 US US13/644,216 patent/US9102678B2/en active Active
- 2012-10-16 CY CY20121100962T patent/CY1113192T1/el unknown
-
2014
- 2014-02-14 JP JP2014026015A patent/JP5827708B2/ja active Active
- 2014-12-23 HK HK14112844.7A patent/HK1199254A1/xx unknown
-
2015
- 2015-06-08 HK HK15105404.2A patent/HK1205102A1/xx unknown
- 2015-07-27 US US14/810,225 patent/US9765078B2/en active Active
-
2017
- 2017-09-18 US US15/707,484 patent/US10414770B2/en active Active
-
2019
- 2019-09-13 US US16/569,809 patent/US11014928B2/en active Active
-
2021
- 2021-05-24 US US17/328,618 patent/US20220041605A1/en not_active Abandoned
-
2023
- 2023-10-19 US US18/490,596 patent/US20240083906A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1205102A1 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
ME00716B (me) | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze | |
EP1957078A4 (en) | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER BY INHIBITING AURORA KINASE | |
HK1096972A1 (en) | Inhibition of syk kinase expression | |
GB2432165B (en) | Method of inhibiting hydrate formation | |
IL189933A0 (en) | Rna antagonist compounds for the inhibition of apo-b100 expression | |
ZA200804253B (en) | Method of inhibiting FLT3 kinase | |
ZA200704106B (en) | Inhibitors of c-fms kinase | |
EP1954290A4 (en) | AS KINASE-HEMMER USES TRICYCLIC COMPOUNDS | |
IL172375A0 (en) | Chinazoline derivatives as aurora kinase inhibitors | |
IL187257A0 (en) | Compositions and methods for inhibition of the jak pathway | |
EP1778693A4 (en) | AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL | |
HK1144392A1 (en) | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | |
GB0608823D0 (en) | Inhibitors of P13 kinase | |
ZA200700826B (en) | Thienopyrimidines useful as Aurora kinase inhibitors | |
ZA200809874B (en) | Method of inhibiting c kit kinase | |
IL182735A0 (en) | Inhibitors of c-fms kinase | |
EP1906967A4 (en) | ABL Kinase Inhibition | |
SI1905773T1 (sl) | Spojine in postopki za inhibiranje mitotične progresije z inhibiranjem aurora kinaze | |
IL182680A0 (en) | Compositions and methods for short interfering nucleic acid inhibition of | |
EP1771203A4 (en) | INHIBITION OF NF-KB | |
EP1605893A4 (en) | TRANS-MEMBRANE ANTIBODY-INDUCED APOPTOSIS INHIBITION | |
PL1905773T3 (pl) | Związki i sposoby hamowania progresji mitotycznej poprzez hamowanie kinazy aurora | |
EP1776140A4 (en) | METHOD FOR INHIBITING VIRAL REPLICATION | |
EP1765334A4 (en) | PRODRUGS OF INHIBITORS OF MITOTIC KINESINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: APPLE INC. COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION - INHIBITION OF AURORA KINASE Effective date: 20121128 |